NT5C2 and acute lymphoblastic leukemia: Collectively, these data identify three activating mechanisms by which NT5C2 mutations increase nucleotidase activity, and pave the way for the development of NT5C2 inhibitors to prevent and reverse purine analogue resistance in T-ALL [66].